RS52941B - Kombinacija alfa 7 nikotinskih agonista i antipsihotika - Google Patents

Kombinacija alfa 7 nikotinskih agonista i antipsihotika

Info

Publication number
RS52941B
RS52941B RS20130387A RSP20130387A RS52941B RS 52941 B RS52941 B RS 52941B RS 20130387 A RS20130387 A RS 20130387A RS P20130387 A RSP20130387 A RS P20130387A RS 52941 B RS52941 B RS 52941B
Authority
RS
Serbia
Prior art keywords
mice
antipsychotic
schizophrenia
disorder
nicotinic
Prior art date
Application number
RS20130387A
Other languages
English (en)
Serbian (sr)
Inventor
Merouane Bencherif
Gregory J. Gatto
Kristen G. Jordan
Terry Hauser
Sharon R. Letchworth
Original Assignee
Targacept Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc. filed Critical Targacept Inc.
Publication of RS52941B publication Critical patent/RS52941B/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
RS20130387A 2008-02-13 2009-02-13 Kombinacija alfa 7 nikotinskih agonista i antipsihotika RS52941B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2828208P 2008-02-13 2008-02-13
PCT/US2009/034062 WO2009102962A2 (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics

Publications (1)

Publication Number Publication Date
RS52941B true RS52941B (sr) 2014-02-28

Family

ID=40902222

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20130387A RS52941B (sr) 2008-02-13 2009-02-13 Kombinacija alfa 7 nikotinskih agonista i antipsihotika

Country Status (25)

Country Link
US (1) US20110059947A1 (https=)
EP (2) EP2633868A1 (https=)
JP (1) JP2011511845A (https=)
KR (1) KR20100113163A (https=)
CN (2) CN103143023A (https=)
AU (1) AU2009214625A1 (https=)
BR (1) BRPI0907570A2 (https=)
CA (1) CA2715268A1 (https=)
CO (1) CO6290706A2 (https=)
CY (1) CY1114492T1 (https=)
DK (1) DK2254598T3 (https=)
EC (1) ECSP10010471A (https=)
ES (1) ES2430622T3 (https=)
HR (1) HRP20130749T1 (https=)
IL (1) IL207389A0 (https=)
MX (1) MX2010008875A (https=)
NZ (1) NZ587312A (https=)
PL (1) PL2254598T3 (https=)
PT (1) PT2254598E (https=)
RS (1) RS52941B (https=)
RU (1) RU2481123C2 (https=)
SG (1) SG188144A1 (https=)
SI (1) SI2254598T1 (https=)
WO (1) WO2009102962A2 (https=)
ZA (1) ZA201005999B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
PE20131394A1 (es) 2010-09-23 2014-01-11 Abbvie Inc Monohidrato de derivados de aza-adamantano
CA2824900A1 (en) * 2011-01-18 2012-07-26 Targacept, Inc. Treatment of cognitive dysfunction in schizophrenia
WO2012151136A1 (en) * 2011-05-03 2012-11-08 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
MX2015004285A (es) * 2012-10-02 2015-08-06 Sumitomo Dainippon Pharma Co Ltd Derivado de imidazol.
JP6807094B2 (ja) * 2016-04-29 2021-01-06 国立大学法人秋田大学 クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN108727416B (zh) * 2017-04-20 2021-03-09 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
EP4274824A1 (en) 2021-01-08 2023-11-15 IFM Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
JP2024502470A (ja) * 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための化合物および組成物
DE102022114269A1 (de) 2022-06-07 2023-12-07 Rational Aktiengesellschaft Gargerät mit einem Selbstreinigungssystem sowie ein Verfahren zum Ändern von Reinigungsparametern für das Gargerät

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5712270A (en) * 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
DK1083889T3 (da) 1998-06-01 2004-04-13 Ortho Mcneil Pharm Inc Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
CA2396351C (en) * 1999-12-10 2009-11-10 Wyeth New therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders
KR100751981B1 (ko) * 2000-06-27 2007-08-28 라보라토리오스 살바트, 에스.에이. 아릴알킬아민으로부터 유도된 카바메이트
AU2001284645A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002016357A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282875A1 (en) 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002016355A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
US6554086B1 (en) * 2000-10-27 2003-04-29 Invacare Corporation Obstacle traversing wheelchair
NZ526580A (en) 2000-12-22 2005-04-29 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
CA2476624A1 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
BR0317019A (pt) * 2002-12-06 2005-10-25 Pharmacia & Upjohn Co Llc Sais cristalinos fumarato de 1-azabiciclo[2.2.2]oct-substituìdo-furo[2,3-c]piridinil- carboxamida e suas composições e preparações
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
WO2005063296A2 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
EP1863485A2 (en) * 2005-03-18 2007-12-12 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions

Also Published As

Publication number Publication date
WO2009102962A2 (en) 2009-08-20
EP2254598A2 (en) 2010-12-01
CN103143023A (zh) 2013-06-12
PT2254598E (pt) 2013-10-16
CO6290706A2 (es) 2011-06-20
RU2010137787A (ru) 2012-03-20
ZA201005999B (en) 2011-05-25
RU2481123C2 (ru) 2013-05-10
HK1147954A1 (en) 2011-08-26
CN101977628A (zh) 2011-02-16
KR20100113163A (ko) 2010-10-20
PL2254598T3 (pl) 2013-12-31
US20110059947A1 (en) 2011-03-10
BRPI0907570A2 (pt) 2019-09-24
EP2633868A1 (en) 2013-09-04
MX2010008875A (es) 2010-08-31
IL207389A0 (en) 2010-12-30
DK2254598T3 (da) 2013-07-29
ECSP10010471A (es) 2010-10-30
WO2009102962A3 (en) 2009-10-08
HRP20130749T1 (en) 2013-10-11
NZ587312A (en) 2011-12-22
CY1114492T1 (el) 2016-10-05
SI2254598T1 (sl) 2013-10-30
JP2011511845A (ja) 2011-04-14
SG188144A1 (en) 2013-03-28
EP2254598B1 (en) 2013-07-10
CA2715268A1 (en) 2009-08-20
AU2009214625A1 (en) 2009-08-20
ES2430622T3 (es) 2013-11-21

Similar Documents

Publication Publication Date Title
RS52941B (sr) Kombinacija alfa 7 nikotinskih agonista i antipsihotika
Echeverria et al. Cotinine: a potential new therapeutic agent against Alzheimer's disease
Nguyen et al. Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPPL/S transgenic mice
US20100178277A1 (en) Methods and compositions for stimulating cells
WO2009135091A1 (en) Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
WO2008036410A2 (en) Methods and compositions for treating amyotrophic lateral sclerosis (als)
WO2022215080A1 (en) A combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders
Zhang et al. Davunetide improves spatial learning and memory in Alzheimer's disease-associated rats
Kim et al. Unacylated Ghrelin protects against age‐related loss of muscle mass and contractile dysfunction in skeletal muscle
Chagraoui et al. 5-HT6 receptors: Contemporary views on their neurobiological and pharmacological relevance in neuropsychiatric disorders
Perkins et al. Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin‐deficient mice and Duchenne muscular dystrophy
Tsai Semax, an analogue of adrenocorticotropin (4–10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome
CN100525764C (zh) 吡唑并吡啶在制备治疗认知缺陷的药物中的应用
Cacabelos Pharmacogenetics in Alzheimer’s disease drug discovery and personalized treatment
HK1147954B (en) Combination of alpha 7 nicotinic agonists and antipsychotics
HK1185794A (en) Combination of alpha 7 nicotinic agonists and antipsychotics
Chhimpa et al. Pharmacotherapy of Alzheimer’s disease
Haynes The effects of fluphenazine on the neuromuscular phenotype in a mouse model of spinal muscular atrophy
EP4366756A1 (en) Sco-spondin-derived polypeptides for enhancing synaptic transmission
Cassidy et al. Physiotherapy management of the ataxias towards best clinical practice: 2016 guideline update
Barrett et al. The European Histamine Research Society 48th Annual Meeting, May 15–18th, 2019 Krakow, Poland
Dowling et al. Investigating feasibility of use of an Android Smart Phone Application (MoveIt) as a clinical outcome measure
Vaghi BDNF translational control as a therapeutic target in Rett syndorme
LaFerla Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease
Hori Developmental Effects of Bilateral Ventral Hippocampal Lesions on Neocortical [capital Delta] FosB Expression and Cognition: Reversal of Cognitive Deficits by Darbepoetin Alfa But Not Clozapine